Effect of AD-5423 on animal models of schizophrenia

Phencyclidine-induced behavioral changes in mice

T. Nagai, Y. Noda, T. Une, K. Furukawa, H. Furukawa, Q. M. Kan, Toshitaka Nabeshima

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

Original languageEnglish
Pages (from-to)269-272
Number of pages4
JournalNeuroReport
Volume14
Issue number2
DOIs
Publication statusPublished - 10-02-2003
Externally publishedYes

Fingerprint

Phencyclidine
Schizophrenia
Animal Models
Haloperidol
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT2 Receptors
Antipsychotic Agents
Serotonin
blonanserin

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Nagai, T. ; Noda, Y. ; Une, T. ; Furukawa, K. ; Furukawa, H. ; Kan, Q. M. ; Nabeshima, Toshitaka. / Effect of AD-5423 on animal models of schizophrenia : Phencyclidine-induced behavioral changes in mice. In: NeuroReport. 2003 ; Vol. 14, No. 2. pp. 269-272.
@article{1a2951a063464d07bade10827cd78378,
title = "Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice",
abstract = "The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.",
author = "T. Nagai and Y. Noda and T. Une and K. Furukawa and H. Furukawa and Kan, {Q. M.} and Toshitaka Nabeshima",
year = "2003",
month = "2",
day = "10",
doi = "10.1097/00001756-200302100-00023",
language = "English",
volume = "14",
pages = "269--272",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Effect of AD-5423 on animal models of schizophrenia : Phencyclidine-induced behavioral changes in mice. / Nagai, T.; Noda, Y.; Une, T.; Furukawa, K.; Furukawa, H.; Kan, Q. M.; Nabeshima, Toshitaka.

In: NeuroReport, Vol. 14, No. 2, 10.02.2003, p. 269-272.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of AD-5423 on animal models of schizophrenia

T2 - Phencyclidine-induced behavioral changes in mice

AU - Nagai, T.

AU - Noda, Y.

AU - Une, T.

AU - Furukawa, K.

AU - Furukawa, H.

AU - Kan, Q. M.

AU - Nabeshima, Toshitaka

PY - 2003/2/10

Y1 - 2003/2/10

N2 - The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

AB - The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0037428772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037428772&partnerID=8YFLogxK

U2 - 10.1097/00001756-200302100-00023

DO - 10.1097/00001756-200302100-00023

M3 - Article

VL - 14

SP - 269

EP - 272

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 2

ER -